REVOLUTION MEDICINES INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Frank K. Clyburn, Jr.

REVOLUTION MEDICINES INC.’s own tally for this item (“Elect Director: Frank K. Clyburn, Jr.”): 147,380,169 for, 512,898 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 61,586,145 for, 15,382 withheld, 0 abstained, 87 not voted.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Sandra J. Horning, M.D.

REVOLUTION MEDICINES INC.’s own tally for this item (“Elect Director: Sandra J. Horning, M.D.”): 126,395,644 for, 21,497,423 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 58,624,501 for, 2,070,239 withheld, 906,788 abstained, 87 not voted.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Sushil Patel, Ph.D.

REVOLUTION MEDICINES INC.’s own tally for this item (“Elect Director: Sushil Patel, Ph.D.”): 126,396,068 for, 21,496,999 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 58,624,501 for, 2,070,239 withheld, 906,788 abstained, 87 not voted.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Thilo Schroeder, Ph.D.

REVOLUTION MEDICINES INC.’s own tally for this item (“Elect Director: Thilo Schroeder, Ph.D.”): 119,696,091 for, 28,196,976 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 56,429,984 for, 4,264,755 withheld, 906,788 abstained, 87 not voted.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT PURSUANT TO THE COMPENSATION DISCLOSURE RULES OF THE SECURITIES AND EXCHANGE COMMISSION ("SAY-ON-PAY").

REVOLUTION MEDICINES INC.’s own tally for this item (“3. On a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC”): 145,265,825 for, 2,597,920 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 83 managers: 60,745,163 for, 845,612 against, 10,752 abstained, 87 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 222 managers: 110,859,263 for, 1,853,989 against, 15,652 abstained, 2,931 not voted, 226,000 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025; and

REVOLUTION MEDICINES INC.’s own tally for this item (“2. The appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 20”): 157,875,830 for, 214,963 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 61,589,923 for, 852 against, 10,752 abstained, 87 not voted.

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.